GMED GLOBUS MEDICAL INC

NYSE globusmedical.com


$ 59.28 $ 0.61 (1.04 %)    

Friday, 17-Oct-2025 12:26:42 EDT
QQQ $ 603.00 $ 5.44 (0.91 %)
DIA $ 461.64 $ 2.29 (0.5 %)
SPY $ 663.19 $ 3.76 (0.57 %)
TLT $ 91.11 $ -0.10 (-0.11 %)
GLD $ 388.62 $ -8.55 (-2.15 %)
$ 58.57
$ 58.62
$ 59.19 x 45
$ 59.30 x 15
$ 58.60 - $ 59.28
$ 51.79 - $ 94.93
836,005
na
7.91B
$ 1.03
$ 22.18
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-20-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-21-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 02-17-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 02-17-2021 12-31-2020 10-K
20 10-28-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-20-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-21-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 02-22-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 07-27-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-04-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 carlsmeds-personalized-spine-implants-get-significant-reimbursement-advantage

Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a ...

 wells-fargo-maintains-overweight-on-globus-medical-lowers-price-target-to-66

Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $76 t...

 globus-medical-affirms-fy2025-adj-eps-guidance-of-300-330-vs-316-est-affirms-fy2025-sales-guidance-of-2800b-2900b-vs-2852b-est

Globus Medical (NYSE:GMED) affirms FY2025 Adj EPS guidance from $3.00-$3.30 to $3.00-$3.30 vs $3.16 analyst estimate. Affirms F...

 globus-medical-q2-adj-eps-086-beats-076-estimate-sales-745342m-beat-738903m-estimate

Globus Medical (NYSE:GMED) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.76 by...

 canaccord-genuity-maintains-buy-on-globus-medical-lowers-price-target-to-90

Canaccord Genuity analyst William Plovanic maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from ...

 needham-reiterates-hold-on-globus-medicalto-hold

Needham analyst David Saxon reiterates Globus Medical (NYSE:GMED) from Hold to Hold.

 globus-medical-expects-q2-sales-to-be-7453m-as-reported-increase-of-184-over-q2-2024

Globus Medical, Inc. also announced today its preliminary sales results for the second quarter ending June 30, 2025. The Compan...

 globus-medical-appoints-keith-pfeil-as-president-and-ceo-effective-july-18-2025-succeeding-daniel-scavilla

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vic...

 globus-medical-reveals-durapro-with-navigation-a-next-generation-oscillating-system-designed-to-safeguard-delicate-tissue

AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, ...

 morgan-stanley-maintains-overweight-on-globus-medical-lowers-price-target-to-68

Morgan Stanley analyst Drew Ranieri maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from ...

 jmp-securities-reiterates-market-perform-on-globus-medicalto-market-perform

JMP Securities analyst David Turkaly reiterates Globus Medical (NYSE:GMED) from Market Perform to Market Perform.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION